SHR-A2102 and Adebrelimab
Phase 3Monoclonal antibody
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-A2102 and Adebrelimab is one of 5 small molecule programs targeting Locally Advanced or Metastatic Urothelial Carcinoma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Locally Advanced or Metastatic Urothelial Carcinoma
#DrugCompanyPhaseTrials
1TRODELVY
GileadPhase 2
Bavencio
EMD SeronoPhase 2
SHR-A2102 and Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
NKTR-255
NNektar Therapeutics
Phase 2
M6223
EMD Serono Research & Development Institute, Inc.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced or Metastatic Urothelial Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-A2102 and Adebrelimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details